Iovance Biotherapeutics (IOVA) Stock Price, Quote, News & History | Benzinga

Iovance Biotherapeutics Inc (IOVA) Stock Price, Quote, News & History

IOVANASDAQ

Trade with Public

Trade with Public

$6.34

0.132.09%

At close: Aug 6, 5:00 PM EST

$6.30

0.091.45%

Pre-Market: 4:09 AM EST

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, before the market open

Conference Call: The most recent conference call started at 8:30 AM, 4 days ago

Click to view the webcast

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$6.34

Volume / Avg.

1.30K / 16.28M

Day Range

- - -

52 Wk Range

1.76 - 6.92

Market Cap

$2.81B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

70

Short Interest

23.95%

Days to Cover

5.91

Recent Iovance Biotherapeutics Inc News

Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 Results

Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should know.

Evette Mitkov

Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday

US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.

Avi Kapoor

Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures fall 250 points, Highpeak Energy shares drop 7%. Other stocks also down in pre-market trading after reporting earnings.

Avi Kapoor

Highpeak Energy Posts Downbeat Q4 Results, Joins Netskope, Descartes Systems And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures fall 250 points, Highpeak Energy shares drop 7%. Other stocks also down in pre-market trading after reporting earnings.

Avi Kapoor

What's Going On With Iovance Biotherapeutics Stock On Friday?

Iovance stock jumps despite no news as investors watch short interest and promising early data from its cancer therapy trial.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-264.18M

Investing Cash Flow (TTM)

-44.87M

Financing Cash Flow (TTM)

287.85M

Free Cash Flow (TTM)

-296.40M

Capital Expenditure (TTM)

-32.21M

Net Change in Cash (TTM)

-21.20M

Analyst Trends and Forecast

1

Feb

1

Mar

1

Apr

1

May

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$2.80B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

8.00

PB Ratio (TTM)

3.97

Earnings Yield % (TTM)

-10.89%

Earnings Yield % (FWD)

-11.36%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$1.60

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$110.77M

Debt to Equity

0.06

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

-

Close

$6.34

Volume / Avg.

1.30K / 16.28M

Day Range

- - -

52 Wk Range

1.76 - 6.92

Market Cap

$2.81B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

70

Short Interest

23.95%

Days to Cover

5.91

About

Sector

Health Care

Industry

Biotechnology

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies persona...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Iovance Biotherapeutics (IOVA) stock?

A

You can purchase shares of Iovance Biotherapeutics (NASDAQ:IOVA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Iovance Biotherapeutics (IOVA) competitors?

A

Other companies in Iovance Biotherapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Iovance Biotherapeutics (IOVA) stock?

A

Iovance Biotherapeutics has a consensus price target of $11.54.

Q

What is the current price for Iovance Biotherapeutics (IOVA)?

A

The stock price for Iovance Biotherapeutics (NASDAQ: IOVA) is $6.3 last updated August 10, 2026 at 4:09 AM EDT.

Q

Does Iovance Biotherapeutics (IOVA) pay a dividend?

A

There are no upcoming dividends for Iovance Biotherapeutics.

Q

When is Iovance Biotherapeutics (NASDAQ:IOVA) reporting earnings?

A

Iovance Biotherapeutics does not have any upcoming earnings scheduled.

Q

Is Iovance Biotherapeutics (IOVA) going to split?

A

There is no upcoming split for Iovance Biotherapeutics.

Q

What sector and industry does Iovance Biotherapeutics (IOVA) operate in?

A

Iovance Biotherapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.